Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients

This study has been completed.
Sponsor:
Collaborator:
Millennium Laboratories
Information provided by:
Pain Management Center of Paducah
ClinicalTrials.gov Identifier:
NCT01052155
First received: January 18, 2010
Last updated: March 11, 2011
Last verified: March 2011
  Purpose

Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)


Condition Intervention
Chronic Pain
Other: Urine Drug Testing

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)

Resource links provided by NLM:


Further study details as provided by Pain Management Center of Paducah:

Primary Outcome Measures:
  • Diagnostic accuracy [ Time Frame: 72 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: February 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Urine Drug Testing
    LC/MS/MS Laboratory Evaluation
    Other Name: In-office Urine Drug Testing (Immunoassay)
Detailed Description:

Recruitment is indicated in patients with chronic pain management with or without controlled substance therapy.

This is a diagnostic accuracy study performed in an interventional pain management referral center in the United States.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with chronic pain management with or without controlled substance therapy.

Criteria

Inclusion criteria:

• Chronic pain management with or without controlled substance therapy.

Exclusion criteria:

None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01052155

Sponsors and Collaborators
Pain Management Center of Paducah
Millennium Laboratories
Investigators
Principal Investigator: Laxmaiah Manchikanti, MD Ambulatory Surgery Center, Paducah
  More Information

No publications provided by Pain Management Center of Paducah

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Laxmaiah Manchikanti, MD/Medical Director, Pain Management Center of Paducah and Ambulatory Surgery Center
ClinicalTrials.gov Identifier: NCT01052155     History of Changes
Other Study ID Numbers: Protocol 26
Study First Received: January 18, 2010
Last Updated: March 11, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Pain Management Center of Paducah:
Controlled substances
Opioids
Benzodiazepines
Illicit drugs
Immunoassay drug testing
Point of care (POC) testing
Liquid Chromatography Tandem Mass Spectometry

Additional relevant MeSH terms:
Chronic Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on July 31, 2014